Korro Bio

Korro Bio

  • Founded: 2019
  • Location: Cambridge, MA
  • Employee range: 50 - 200
  • Clinical stage: RD
  • Therapy area: Liver conditions
  • Drug types: HEP, NEU, OPH
  • Lead product: OPERA platform
  • Product link: https://www.korrobio.com/our-approach/
  • Funding: $116M B Jan 2022; $91.5M A Sep 2020; $4M seed Oct 2019
  • Investors: Atlas



job board

Short description:

RNA-editing Drugs

Drug notes:

Also RD CNS conditions, RD eye conditions

Long description:

Korro Bio is pioneering RNA editing as a therapeutic modality. RNA editing enables disease-causing mutations to be fixed before proteins are synthesized. Korro is using their Oligonucleotide Promoted Editing of RNA (OPERA) platform to identify the most effective RNA editing tools. OPERA revolves around co-opting the body’s natural base editing system, ADAR, a protein that makes targeted edits to a single RNA base, with Korro’s synthetic oligonucleotide guides to target specific RNA sequences. This circumvents permanently modifying a patient’s genome but still requires specificity and flexibility in delivery mechanisms. Korro’s focus areas include genetic diseases of the liver, central nervous system and eye.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com